GemPharmatech Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Jing Zhao
Chief executive officer
CN¥859.0k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 6.9yrs |
| CEO ownership | n/a |
| Management average tenure | 1.7yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
CEO
Jing Zhao (43 yo)
6.9yrs
Tenure
CN¥859,000
Compensation
Dr. Jing Zhao is CEO at GemPharmatech Co., Ltd. and has been its GM and Director since January 2018 and was its Secretary. She has experience in animal model creation and analysis.She is currently the Dep...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 6.9yrs | CN¥859.00k | no data | |
| Chief Financial Officer | 1.2yrs | CN¥1.06m | no data | |
| Deputy GM & Director | 6yrs | CN¥823.70k | no data | |
| Deputy GM & Director | 1.7yrs | CN¥657.10k | no data | |
| Board Secretary | 1.7yrs | CN¥975.00k | no data | |
| Chief Technology Officer | no data | no data | no data | |
| Deputy Director of Functional Pharmacodynamics Center | no data | no data | no data |
1.7yrs
Average Tenure
41yo
Average Age
Experienced Management: 688046's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 6.9yrs | CN¥859.00k | no data | |
| Deputy GM & Director | 7yrs | CN¥823.70k | no data | |
| Deputy GM & Director | 1.5yrs | CN¥657.10k | no data | |
| Director | 1.2yrs | no data | no data | |
| Director | 1.2yrs | no data | no data | |
| Independent Director | 4.2yrs | CN¥100.00k | no data | |
| Independent Director | 4.2yrs | CN¥100.00k | no data | |
| Chairman of the Board | 7yrs | CN¥1.91m | no data | |
| Independent Director | 4.2yrs | CN¥100.00k | no data | |
| Supervisor | 4.2yrs | no data | no data | |
| Chairman of the Board of Supervisors | 15.2yrs | no data | no data | |
| Employee Representative Supervisor | 4.2yrs | no data | no data |
4.2yrs
Average Tenure
45yo
Average Age
Experienced Board: 688046's board of directors are considered experienced (4.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 19:59 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GemPharmatech Co., Ltd. is covered by 15 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhu Chen | Citic Securities Co., Ltd. |
| Kai Wang | Citic Securities Co., Ltd. |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |